First therapy for rare joint tumor approved by the FDA

Earlier this month, the U.S. Food and Drug Administration approved Daiichi Sankyo’s Turalio, the first therapy for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not responsive to improvement with surgery. TGCT can cause incapacitating symptoms for patients such as pain, stiffness and limitation of movement.

Click here to view the entire article.